WI Harper Group’s Portfolio is Battling the Novel Coronavirus

WI Harper Group | February 3, 2020

Health and safety are our biggest concerns during this Lunar New Year. The constantly updated Coronavirus statistics tug at the heartstrings of hundreds of millions of Chinese. In this battle against the Coronavirus, WI Harper Group and its portfolio companies are actively contributing to the society.

| Edan’s’ first batch of electrocardiogram machines were put into use at Huoshenshan Hospital

The Huoshenshan Hospital began operations after the rapid construction. The first batch of Edan electrocardiogram machines have been deployed at Huoshenshan Hospital and are fully operating. At the moment, the medical instruments that will be installed and used in Leishenshan Hospital have also arrived in Wuhan. Within just a week, Edan has deployed more than 6,000 devices, including patient monitors, diagnostic ECGs and blood gas analyzers, magnetic immunoanalyzer, and pulse oximeters, to Renmin Hospital of Wuhan University, the First People’s Hospital of Jiangxia, Tianyou Hospital Affiliated to Wuhan University of Science & Technology, Hubei Provincial Hospital of Integrated Chinese & Western Medicine, and many more hospitals in China.

With its global vision, continuous innovation and excellent service, Edan (SHE: 300206) has become a well-known provider of healthcare products, solutions and services. The company covers six business segments, including patient monitoring, diagnostic ECGs, ultrasound imaging, OB & GYN, IVD, and digital health. In China, Edan has extended its reach across the country, providing innovative, high-quality products and services to more than 30,000 medical institutions. It has five R&D centers and 20 subsidiaries. Edan’s products are exported to more than 170 countries and regions. Edan is committed to providing quality products and solutions that meet the clinical needs of medical institutions.

Edan can quickly provide Medical instruments that help combating Coronavirus, such as vital signs monitors, patient monitors, oximeters, ECG machines, blood gas biochemical analyzers, magnetic immunoanalyzer, whole blood specific protein detection equipment, ultrasonic imaging devices, and etc.

| MedicalSystem’s critical care system is on the front line

As a listed leader of CIS in the field of critical and severe diseases, MedicalSystem has implemented the integrated intelligent emergency system for Wuhan Emergency Care Center. This includes Smart Emergency platform, ambulance dispatch system, and specialist consultation system, and provides information system of ICU wards for more than 30 hospitals in Wuhan, including Tongji Hospital and Wuhan Central Hospital. The system works well during the fight against Coronavirus. At the moment, MedicalSystem’s critical care system is still at the forefront. Smart Emergency platform continued to receive and treat patients. Smart Ambulance escorts patients to hospitals. Critical care system provides specialist video consultation for seriously ill patients, race against time to save lives. In Wuhan, MedicalSystem engineers are standing by 24 hours a day to provide the hospital with support and maintenance of the system operations to ensure the medical demands are met.

On January 23 and January 25, Wuhan Novel Coronavirus Prevention and Control Center announced Huoshensha and Leishenshan hospitals in Wuhan which are “Xiaotangshan” model hospitals. MedicalSystem Jilin subsidiary responded promptly, and decided to donate ICU information systems to the hospitals.

| iKang Healthcare Group has pledged 2 million RMB to the team that developed the coronavirus vaccine and to be first used in China

iKang Healthcare Group has made a strong commitment to encourage fast development of a vaccine against the 2019 nCoV coronavirus. iKang announced to award 2 million RMB to the team that successfully develops the coronavirus vaccine that will be applied clinically in China, of which 1 million RMB would be used as an individual reward to the leader of the R&D team. iKang supports and looks forward to the fast development of the coronavirus vaccine. The early production and application of vaccines can ensure health of the public.

iKang is the pioneer and leading provider of healthcare management services in China. Through a number of its brands, iKang provides comprehensive and high-quality medical examination, disease screening, dental services, private doctors, occupational medicine, vaccination, anti-aging and other health management and medical services to groups, families, and individuals.

| IIPharma proposes potential new applications for older drugs against novel coronaviruses

It takes 8 to 12 years to develop a new drug. It is not likely to achieve a timely development of drugs to combat coronaviruses. IIPharma uses Intelligent Brain TM to search for potential solutions by repurposing old drugs and traditional Chinese medicine (as shown in the table below). Initial results are being made public in the hope of providing potential solutions for clinicians.

The four schemes above are based on publicly available research data and the analysis of old drugs. Corresponding molecular, biochemical, cellular mechanisms of action, and a few animal experiments, are available in the original references in the appendix. These drugs may be effective as a monotherapy or in combination with other drugs.

IIPharma is an early-stage startup and hasn’t established its own pharmacology laboratory, hence is not able to validate the results provided above. IIPharma called on experts to experiment on these drug molecules based on their judgements and contribute to the rapid elimination of the 2019-nCov.

Disclaimer: the above four schemes are scientific research results and do not guarantee any clinical efficacy. Patients should follow the guidance of doctors.

Translated from: https://mp.weixin.qq.com/s/KYWLRKRF5t1N7xzbMIYNiA

WI Harper Group’s Portfolio is Battling the Novel Coronavirus

Resvent Medical is a Shenzhen, China-based medical device and solution company focused on medical respiration & ventilation field, with its core management team having spun out of Mindray’s hospitals respiratory division, with over a decade of experience in homecare devices, clinical respiratory healthcare, intelligent information system, related consumable & accessories and value added services, and capable of building a globally competitive respiratory player – i.e. the RESMED of China.